Start Date
October 31, 2017
Primary Completion Date
October 31, 2021
Study Completion Date
December 31, 2021
Durvalumab
Immunotherapy with Durvalumab after ASCT
Collaborators (1)
Celgene
INDUSTRY
Insel Gruppe AG, University Hospital Bern
OTHER